TPST vs. MGNX, ZNTL, OPTN, WHWK, CTNM, CLYM, VXRT, BYSI, VIRI, and OCX
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include MacroGenics (MGNX), Zentalis Pharmaceuticals (ZNTL), OptiNose (OPTN), Whitehawk Therapeutics (WHWK), Contineum Therapeutics (CTNM), Climb Bio (CLYM), Vaxart (VXRT), BeyondSpring (BYSI), Virios Therapeutics (VIRI), and OncoCyte (OCX). These companies are all part of the "pharmaceutical products" industry.
Tempest Therapeutics vs. Its Competitors
MacroGenics (NASDAQ:MGNX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
Tempest Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -36.23%. MacroGenics' return on equity of -59.84% beat Tempest Therapeutics' return on equity.
96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 13.0% of MacroGenics shares are owned by insiders. Comparatively, 4.7% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
MacroGenics currently has a consensus target price of $5.71, indicating a potential upside of 283.51%. Tempest Therapeutics has a consensus target price of $30.00, indicating a potential upside of 348.43%. Given Tempest Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tempest Therapeutics is more favorable than MacroGenics.
In the previous week, MacroGenics had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 3 mentions for MacroGenics and 1 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.89 beat MacroGenics' score of 0.64 indicating that Tempest Therapeutics is being referred to more favorably in the news media.
Tempest Therapeutics has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
MacroGenics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.95, suggesting that its share price is 295% less volatile than the S&P 500.
Summary
MacroGenics beats Tempest Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TPST) was last updated on 7/16/2025 by MarketBeat.com Staff
Free TPST Stock Alerts